
AstraZeneca signs $2 bln agreement with Quell to develop cell therapies
AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
The agreement ...